stage IV grade 2 follicular lymphoma
Showing 26 - 50 of >10,000
Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma Trial in Palo Alto (Ibrutinib, Radiation
Active, not recruiting
- Grade 1 Follicular Lymphoma
- +6 more
- Ibrutinib
- +2 more
-
Palo Alto, CaliforniaStanford University, School of Medicine
Jun 13, 2022
Composite Lymphoma, Grade 3b Follicular Lymphoma, Stage I DLBCL Trial in Seattle (drug, other, biological)
Completed
- Composite Lymphoma
- +9 more
- Cyclophosphamide
- +6 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Sep 22, 2020
B-Cell Non-Hodgkin Lymphoma, DLBCL, Not Otherwise Specified, High Grade B-Cell Lymphoma Trial in Seattle (Acalabrutinib,
Recruiting
- B-Cell Non-Hodgkin Lymphoma
- +7 more
- Acalabrutinib
- Axicabtagene Ciloleucel
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Dec 9, 2022
Recurrent DLBCL, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma Trial in Duarte (Biopsy,
Not yet recruiting
- Recurrent Diffuse Large B-Cell Lymphoma
- +11 more
- Biopsy
- +5 more
-
Duarte, CaliforniaCity of Hope Medical Center
Jan 3, 2023
Recurrent DLBCL, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma Trial in Houston (other, drug,
Recruiting
- Recurrent Diffuse Large B-Cell Lymphoma
- +3 more
- Laboratory Biomarker Analysis
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Jul 26, 2022
Follicular Lymphoma Trial in Worldwide (Mosunetuzumab (IV), Tocilizumab, Lenalidomide)
Recruiting
- Follicular Lymphoma
- Mosunetuzumab (IV)
- +3 more
-
Duarte, California
- +21 more
Jan 10, 2023
HIV Infection, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Plasmablastic Lymphoma Trial in United States (procedure, drug,
Recruiting
- HIV Infection
- +10 more
- Autologous Hematopoietic Stem Cell Transplantation
- +7 more
-
La Jolla, California
- +3 more
Dec 7, 2022
MALT, Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma Trial in Atlanta, Columbus (drug, biological,
Completed
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
- +8 more
- PI3K inhibitor BKM120
- +3 more
-
Atlanta, Georgia
- +1 more
Jun 27, 2022
Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Large B-cell Lymphoma Trial in Kaohsiung, Taipei
Recruiting
- Diffuse Large B Cell Lymphoma
- +4 more
- CD19-targeted chimeric antigen receptor T-cell
-
Kaohsiung, Taiwan
- +2 more
Oct 25, 2022
Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic Hodgkin Lymphoma, Recurrent
Not yet recruiting
- Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
- +21 more
- Biopsy
- +8 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Apr 7, 2023
Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL Trial in Boston
Not yet recruiting
- Refractory Aggressive B-cell Lymphomas
- +12 more
- ACALABRUTINIB
- +2 more
-
Boston, Massachusetts
- +1 more
Oct 13, 2022
Adult Grade III Lymphomatoid Granulomatosis, Cutaneous B-cell Non-Hodgkin Lymphoma, MALT Trial in Duarte (biological, procedure,
Active, not recruiting
- Adult Grade III Lymphomatoid Granulomatosis
- +23 more
- autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells
- +2 more
-
Duarte, CaliforniaCity of Hope Medical Center
Jan 4, 2023
Follicular Lymphoma, Grade 1, Follicular Lymphoma, Grade 2, Follicular Lymphoma Grade 3A Trial in Italy (OFATUMUMAB)
Completed
- Follicular Lymphoma, Grade 1
- +2 more
-
Alessandria, AL, Italy
- +26 more
Jun 16, 2022
Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma, Recurrent DLBCL Trial in Atlanta, Columbus (other, drug, biological)
Recruiting
- Grade 3a Follicular Lymphoma
- +14 more
- Laboratory Biomarker Analysis
- +2 more
-
Atlanta, Georgia
- +1 more
May 31, 2022
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma Trial in
Recruiting
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +13 more
- Polatuzumab Vedotin
- +3 more
-
Scottsdale, Arizona
- +11 more
Aug 23, 2022
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue,
Suspended
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +23 more
- Lenalidomide
- +2 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Feb 23, 2022
B-Cell Non-Hodgkin Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma Trial in Palo Alto (biological, other,
Active, not recruiting
- B-Cell Non-Hodgkin Lymphoma
- +7 more
- Anti-OX40 Antibody BMS 986178
- +3 more
-
Palo Alto, CaliforniaStanford University, School of Medicine
May 3, 2022
Recurrent Chronic Lymphocytic Leukemia, Recurrent DLBCL, Recurrent Follicular Lymphoma Trial in Seattle (Nivolumab)
Recruiting
- Recurrent Chronic Lymphocytic Leukemia
- +17 more
- Nivolumab
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Aug 16, 2022
MALT, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma Trial in Columbus (drug, biological,
Active, not recruiting
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
- +9 more
- BTK inhibitor PCI-32765
- +5 more
-
Columbus, OhioOhio State University Medical Center
Jun 27, 2022
Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma Trial in Atlanta (drug, biological,
Recruiting
- Grade 1 Follicular Lymphoma
- +7 more
- Acalabrutinib
- +3 more
-
Atlanta, GeorgiaEmory University Hospital/Winship Cancer Institute
Dec 7, 2021
Hematopoietic and Lymphoid Cell Tumor, Recurrent DLBCL, Recurrent High Grade B-Cell Lymphoma Trial in Houston (Anakinra,
Active, not recruiting
- Hematopoietic and Lymphoid Cell Neoplasm
- +8 more
- Anakinra
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Aug 22, 2022
B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Burkitt Lymphoma, Grade 1 Follicular Lymphoma,
Active, not recruiting
- B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma
- +11 more
- Lenalidomide
- +2 more
-
Atlanta, Georgia
- +1 more
Apr 18, 2022
DLBCL, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma Trial (biological, procedure, drug,
Not yet recruiting
- Diffuse Large B-Cell Lymphoma
- +6 more
- Axicabtagene Ciloleucel
- +10 more
- (no location specified)
Jan 13, 2023
Recurrent DLBCL, Recurrent DLBCL, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma Trial in Seattle
Recruiting
- Recurrent Diffuse Large B-Cell Lymphoma
- +8 more
- Cyclophosphamide
- +3 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Dec 30, 2022
Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive, Hepatosplenic T-Cell Lymphoma Trial
Completed
- Anaplastic Large Cell Lymphoma, ALK-Negative
- +9 more
- Autologous Hematopoietic Stem Cell Transplantation
- +8 more
-
Duarte, California
- +7 more
Nov 4, 2022